MYRIAD GENETICS INC
Myriad Genetics develops and commercializes molecular diagnostic tests for patients and healthcare providers. Its testing helps assess disease risk and progression, guide treatment decisions, screen for prenatal conditions, and inform medication selection. The company organizes its testing across Oncology, Women’s Health, and Mental Health. Its products include hereditary cancer tests such as MyRisk, oncology tests including MyChoice CDx and Precise MRD, prenatal screens such as Prequel and Foresight, and GeneSight, which helps clinicians consider how genetics may affect response to mental health medications. Myriad primarily sells tests through its sales force and marketing efforts in the United States and Japan, and reaches customers in Europe and Asia-Pacific through indirect channels and partnerships. It also provides biopharmaceutical services including biomarker identification and validation, companion diagnostic development and registration, and commercialization. Myriad is headquartered in Salt Lake City, Utah.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $MYGN in the last 30 days.
See all $MYGN insider activity →Myriad Genetics reported Q3 2026 revenue of $202.7M, beating estimates by 6.1%, and adjusted EPS of -$0.11, beating estimates by 44.9%. The company raised its full-year revenue guidance to $785M. Despite improvements, operating margin and free cash flow declined.
MYRIAD GENETICS INC (MYGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Myriad Genetics Reports Third Quarter 2026 Financial Results; Raises Mid-Point of Full-Year 2026 Revenue Guidance Following Solid Execution Definitive Agreement to Sell Prenatal Health Business to Support Strategic Growth Initiatives Highl ights • Third quarter 2026
Labcorp announced acquisitions totaling over $1 billion, including BioReference Health for up to $872 million and Myriad Genetics' Prenatal Health business for $210 million. The deals are expected to add $410 million in first-year revenue. Labcorp aims to expand diagnostic services, while Opko Health will focus on biopharmaceuticals.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning MYGN (MYRIAD GENETICS INC). Coverage has skewed bullish: 4 bullish, 0 neutral, and 1 bearish.
Recent MYGN coverage spans earnings, mergers & acquisitions and technology.
Positive earnings surprise and guidance lift likely support upside.
The guidance raise and cash sale are expected to boost investor confidence
Neutral to slightly negative as Myriad exits a segment.
Positive clinical data may boost expectations for Precise MRD commercial adoption and future revenue.
Divestiture provides cash and focus, boosting the stock.
AlphAI scores every news story that mentions MYGN with an AI model for sentiment and relevance, and aggregates insider trades from MYRIAD GENETICS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Myriad Genetics reported Q3 2026 revenue of $202.7M, beating estimates by 6.1%, and adjusted EPS of -$0.11, beating estimates by 44.9%. The company raised its full-year revenue guidance to $785M. Despite improvements, operating margin and free cash flow declined.
MYRIAD GENETICS INC (MYGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Myriad Genetics Reports Third Quarter 2026 Financial Results; Raises Mid-Point of Full-Year 2026 Revenue Guidance Following Solid Execution Definitive Agreement to Sell Prenatal Health Business to Support Strategic Growth Initiatives Highl ights • Third quarter 2026
Labcorp announced acquisitions totaling over $1 billion, including BioReference Health for up to $872 million and Myriad Genetics' Prenatal Health business for $210 million. The deals are expected to add $410 million in first-year revenue. Labcorp aims to expand diagnostic services, while Opko Health will focus on biopharmaceuticals.
Myriad Genetics (MYGN) reported data from the MONSTAR-SCREEN-3 study, showing its Precise MRD™ platform detected cancer DNA before recurrence in colorectal and pancreatic cancer patients, with a median lead time of four months. The findings will be presented at the ESMO Congress 2026.
Washington Trust Bancorp (WASH) rose 5% after beating Q3 2026 estimates. Doximity (DOCS) gained 7.3% following a partnership with Wolters Kluwer. Myriad Genetics (MYGN) surged 22.2% after selling its Prenatal Health unit to Labcorp. Arhaus (ARHS) climbed 6.5% on an upgrade and price target raise. Gartner (IT) increased 4.5% after price target hikes.
Myriad Genetics (MYGN) surged 40% after agreeing to sell its Prenatal Health business to Labcorp for $210M. Moleculin Biotech (MBRX) rose 15% on AML trial progress. Femasys (FEMY) and Revolution Medicines (RVMD) each gained 7% on commercial and clinical developments.
MYRIAD GENETICS INC (MYGN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp Transaction to benefit patients through expanded access and support Myriad’s strategic priorities SALT LAKE CITY and BURLINGTON, N.C., October 20,
Myriad Genetics (MYGN) will sell its Prenatal Health unit to Labcorp for $210M in cash, plus inventory value. The deal is subject to regulatory approval and expected to close by early 2027. Myriad aims to focus on cancer diagnostics, while Labcorp expands its testing services.
SOPHiA GENETICS and Myriad Genetics collaborate to develop a prostate cancer companion diagnostic using PrGIS, a biomarker for homologous recombination deficiency. Myriad's MyChoice CDx test, currently used in ovarian cancer, will be expanded for prostate cancer. The partnership aims to evaluate PrGIS in clinical trials and enable global laboratory testing. Myriad will present research at the European Society for Medical Oncology Congress 2026.
Myriad Genetics (NASDAQ: MYGN) will report Q3 2026 earnings on November 4, 2026, with a conference call scheduled for the same day. The company promoted Vishal Sikri to Executive Vice President - Commercial, effective September 16, 2026, following the departure of Brian Donnelly. Myriad reaffirmed its full-year 2026 financial guidance without providing updated figures.
